Why the study?
Does the CMV antigenemia test accurately detect CMV infection compared to classical markers in kidney transplant recipients?
Does the CMV antigenemia test accurately detect CMV infection compared to classical markers in kidney transplant recipients?
The CMV antigenemia test is highly sensitive and specific for early detection of CMV infection in kidney transplant recipients, outperforming classical markers like viremia and culture.
This is the authors' abstract. We don't add key points for this paper.
Abstracts We evaluated how accurately a CMU antigenemia test correlated with classical CMU infection markers. We studied 91 kidney transplant recipients from February 1991 to June 1992. Antigenemia (pp65 antigen) was positive in 100 % of cases of primary infection and in 70 % of cases of reactivation and/or reinfection. Furthermore, antigenemia detected more infections (71 %) than viremia (16 %). The antigenemia test proved to be highly specific: it remained consistently negative in 22 seronegative patients, as well as in 19 of 20 seropositive recipients without recurrent infection. pp 65 Antigen in the polymorphonuclear leukocytes was detected earlier than, or simultaneously with, virus culture in 78 % of cases and became positive before serologic tests of primary and secondary infection in nearly 90 % of cases. Most importantly, the antigenemia test detected all of the symptomatic cases.
Answers are grounded in this paper and cite their sources.
May support antigenemia for earlier CMV detection in kidney recipients; leaves open need for prospective validation before practice change.
No takes yet. Share an insight, caveat, or question.
Lamy et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: